Drugs / decernotinib
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01886209 | Jun → Aug 2013 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT00789126 | Oct 2008 → ? | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT01754935 | Jan 2013 → Jan 2014 | rheumatoid arthritis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT01590459 | Apr 2012 → Jul 2014 | rheumatoid arthritis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT01052194 | Feb 2010 → Jul 2011 | rheumatoid arthritis | Vertex Pharmaceuticals Incorporated | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01830985 | Apr 2013 → Jul 2014 | rheumatoid arthritis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2014-01-29 | Vertex Pharmaceuticals Incorporated | Results Vertex Reports Full-Year and Fourth Quarter 2013 Financial Results and Provides Financial Guidance for 2014 vrtx.com ↗
Vertex today announced top-line 24-week results from a Phase 2b study of the Janus kinase 3 (JAK3) inhibitor VX-509 in people with moderate to severe rheumatoid arthritis (RA) who continued to receive stable doses of methotrexate during the study. |
| 2013-10-18 | Vertex Pharmaceuticals Incorporated | Results Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study vrtx.com ↗
All doses of VX-509 showed statistically significant ACR20 and ACR50 responses versus placebo and statistically significant improvement from baseline in DAS28 versus placebo. |
| 2011-11-05 | Vertex Pharmaceuticals Incorporated | Results Phase 2 Data for Selective Oral JAK3 Inhibitor VX-509 Show Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis vrtx.com ↗
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from a Phase 2a study of the investigational selective oral JAK3 inhibitor VX-509. |
| 2011-09-06 | Vertex Pharmaceuticals Incorporated | Results Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis vrtx.com ↗
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-01-29 | Vertex Pharmaceuticals Incorporated | Vertex Reports Full-Year and Fourth Quarter 2013 Financial Results and Provides Financial Guidance for 2014 vrtx.com ↗ |
| 2013-10-18 | Vertex Pharmaceuticals Incorporated | Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study vrtx.com ↗ |
| 2011-11-05 | Vertex Pharmaceuticals Incorporated | Phase 2 Data for Selective Oral JAK3 Inhibitor VX-509 Show Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis vrtx.com ↗ |
| 2011-10-24 | Vertex Pharmaceuticals Incorporated | Vertex Announces Presentation of New Data for Oral JAK3 Inhibitor VX-509 at Annual Meeting of the American College of Rheumatology vrtx.com ↗ |
| 2011-09-06 | Vertex Pharmaceuticals Incorporated | Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis vrtx.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | decernotinib | “Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.” PMID 27084959 ↗ Apr 2016 |
| Known as | Adelatinib | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039513 ↗ |
| Known as | VRT-831509 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039513 ↗ |
| Known as | VX-509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01590459 ↗ |
| Action | Inhibit | “VX-509, a JAK3 inhibitor” NCT01052194 ↗ |
| Modality | Small molecule | — CHEMBL3039513 ↗ |
| Route | Oral | “50 mg oral tablet” NCT01590459 ↗ |
| Target | JAK3 | “VX-509, a JAK3 inhibitor” NCT01052194 ↗ |